

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

**NOTE: This special called meeting will be held virtually via Zoom webinar.**

Thursday, September 15, 2022  
1:00 P.M. to 4:00 P.M. (Eastern)

**Access Information**

Smartphone/Web	Dial-In
<a href="https://magellanhealth.zoom.us/j/94900334935">https://magellanhealth.zoom.us/j/94900334935</a> Webinar ID: 949 0033 4935 Password: 563831	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 949 0033 4935 Passcode: 563831

**AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
  - a. Approval of May 2022 Meeting Minutes
- IV. New Business**
  - a. New Products to Market to be reviewed as single products:
    - i. Quviviq™ (Sedative Hypnotic Agents)
    - ii. Igalmi™ (Sedative Hypnotic Agents)
    - iii. Ibsrela® (GI Motility Agents)
    - iv. Mounjaro™ (GLP-1 Receptor Agonists)
    - v. Vtama® (Topical Psoriasis Agents)
    - vi. Voquezna™ (H. Pylori Treatment)
    - vii. Camzyos™ (Non-PDL Medication)
- V. Therapeutic Classes with Recommended Changes**
  - a. Ace Inhibitors
  - b. Anticonvulsants: Second Generation
  - c. Antidepressants: Tricyclics
  - d. Dopamine Receptor Agonists
  - e. Antipsychotics: Injectable
  - f. Beta-Blockers
  - g. Calcium Channel Blockers (Non-DHP)
  - h. Movement Disorders
  - i. Pulmonary Arterial Hypertension (PAH) Agents
- VI. Consent Agenda**
  - a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> <li>• Alzheimer's Agents</li> <li>• Angiotensin Modulators (Angiotensin Receptor Blockers)</li> <li>• Angiotensin Modulator Combinations</li> <li>• Antianginal &amp; Anti-Ischemic</li> <li>• Antiarrhythmics, Oral</li> <li>• Anticoagulants</li> <li>• Anticonvulsants: Carbamazepine Derivatives</li> <li>• Anticonvulsants: First Generation</li> <li>• Antidepressants, Other</li> <li>• Antidepressants, SNRI</li> <li>• Antidepressants, SSRI</li> </ul>	<ul style="list-style-type: none"> <li>• Antiparkinson's Agents (Parkinson's Disease)</li> <li>• Antipsychotics: First-Generation (oral)</li> <li>• Antipsychotics: Second-Generation (oral)</li> <li>• Anxiolytics</li> <li>• Bladder Relaxant Preparations</li> <li>• BPH Treatments</li> <li>• Calcium Channel Blockers (DHP)</li> <li>• Lipotropics, Other</li> <li>• Lipotropics, Statins</li> <li>• Platelet Aggregation Inhibitors</li> <li>• Stimulants and Related Agents</li> <li>• Tobacco Cessation Products/Smoking Cessation</li> </ul>
---	---

**VII. Adjournment**

a. Schedule of Upcoming Meetings

i. **November 17, 2022**

ii. **January 19, 2023**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.